EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal impact of CYP2D6 and CYP2C19 metabolizer status on antidepressant response: The role of Pharmacogenetic mismatch

Alessandro Serretti, Stefano Barlati, Lisa Buson, Valentina Menesello, Anna Magistrali, Rosana Carvalho Silva, Giulia Perusi, Gabriele Nibbio, Stefano Bignotti, PANDORA study group, Giovanni Battista Tura, Antonio Vita und 4 weitere

Journal of Affective Disorders · 2026

DOI: 10.1016/j.jad.2025.120724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Alessandro Serretti und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and surgery, Kore University of Enna, Italy; Oasi Research Institute-IRCCS, Troina, Italy. Electronic address: alessandro.serr…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Major Depressive Disorder, Cytochrome P-450 CYP2C19, Antidepressive Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pharmacogenetic (PGx) guidance for antidepressants focuses on cytochrome (CYP) 2D6 and 2C19, yet real-world evidence on clinically mismatched prescriptions i.e., drugs whose metabolism is not concordant with a patient's PGx phenotype, remains limited. METHODS: In this 12-week prospective study we genotyped 244 outpatients with major depressive disorder (MDD) and classified their current antidepressant as CYP mismatch (n = 114, 46.7 %) or no mismatch (n = 130, 53.3 %). Longitudinal change in Hamilton Depression Rating Scale (HAMD) percentage improvement was analysed with a mixed-effects model. Safety was assessed with the Udvalg for Kliniske Undersøgelser (UKU) scale. RESULTS: The primary model showed a detrimental effect of mismatch on HAM-D improvement (β = -14.65 ± 7.42 %, p = 0.048) and a non-significant trend for time × mismatch interaction (β = 1.30 ± 0.76 %/week, p = 0.088). By week 12, mean improvement was 59.3 ± 25.6 % in the no-mismatch group versus 54.9 ± 28.8 % in mismatch. Overall response (32.1 % vs 37.9 %, p = 0.46) and remission rates (43.8 % vs 50.5 %, p = 0.39) did not differ. Conversely, UKU global scores were significantly higher in mismatch both at week 8 (1.43 ± 1.23 vs 1.07 ± 1.16, p = 0.025) and week 12 (1.03 ± 1.16 vs 0.72 ± 1.09, p = 0.048). CONCLUSIONS: While categorical response and remission rates did not differ between groups and numerically favored the mismatch group, side-effect burden was modestly higher with mismatch; continuous trajectories nevertheless showed a small but consistent disadvantage associated with mismatch.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2D6Major Depressive DisorderCytochrome P-450 CYP2C19Antidepressive AgentsHumansMaleFemaleMiddle AgedAdultProspective StudiesGenotypeLongitudinal StudiesTreatment OutcomePharmacogenetics

Stichwörter der Autor:innen

AntidepressantMajor depressionPharmacogeneticsResistant depression

Substanzen

Cytochrome P-450 CYP2D6Cytochrome P-450 CYP2C19Antidepressive AgentsCYP2C19 protein, human

Autor:innen und Institutionen

  • Department of Medicine and surgery, Kore University of Enna, Italy; Oasi Research Institute-IRCCS, Troina, Italy. Electronic address: alessandro.serretti@icloud.com.
  • Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
  • Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
  • Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Förderung

  • Ministero della Salute

Zitieren

APA

Serretti, A., Barlati, S., Buson, L., Menesello, V., Magistrali, A., Silva, R. C., Perusi, G., Nibbio, G., Bignotti, S., PANDORA study group, Tura, G. B., Vita, A., Ferri, R., Fabbri, C., Gennarelli, M., & Minelli, A. (2026). Longitudinal impact of CYP2D6 and CYP2C19 metabolizer status on antidepressant response: The role of Pharmacogenetic mismatch. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120724

Vancouver

Serretti A, Barlati S, Buson L, Menesello V, Magistrali A, Silva RC, et al. Longitudinal impact of CYP2D6 and CYP2C19 metabolizer status on antidepressant response: The role of Pharmacogenetic mismatch. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.120724

BibTeX
@article{Serretti2026,
  author = {Serretti, Alessandro and Barlati, Stefano and Buson, Lisa and Menesello, Valentina and Magistrali, Anna and Silva, Rosana Carvalho and Perusi, Giulia and Nibbio, Gabriele and Bignotti, Stefano and PANDORA study group, PANDORA study group and Tura, Giovanni Battista and Vita, Antonio and Ferri, Raffaele and Fabbri, Chiara and Gennarelli, Massimo and Minelli, Alessandra},
  title = {Longitudinal impact of CYP2D6 and CYP2C19 metabolizer status on antidepressant response: The role of Pharmacogenetic mismatch},
  journal = {Journal of Affective Disorders},
  year = {2026},
  doi = {10.1016/j.jad.2025.120724}
}
Kostenlos starten →